Sight Sciences opened higher at $10.93, compared with its previous close of $10.92. In the last trading session, the stock traded between $10.64 and $11.60. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Sight Sciences is now worth
$ 46.76
Resulting in a loss of
$ 53.24 (53.24%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
+$0.07 (+0.63%)
Day High
$11.60
Day Low
$10.64
Day Open
$10.93
Prev Close
$10.92
Volume
4,02,525
1W Return
13.62%
1M Return
22.56%
3M Return
41.96%
6M Return
106.95%
1Y Return
56.09%
Market Cap ($ Mn)
611
PE Ratio
-
PB Ratio
8.84
PEG Ratio
-
ROE
-52.87%
ROCE
-29.52%
EPS (TTM)
$-0.12
1 Week
13.62%
1 Month
22.56%
3 Months
41.96%
6 Months
106.95%
9 Months
98.72%
Sight Sciences Q3FY26 Results: Revenue rises 25% YoY to $24.9 million
Revenue rose 25% YoY to $24.9 million, a record high for the quarter. IDE segment revenue surged 45% sequentially to $3.9 million on higher utilization. Full-year 2026 revenue guidance raised to $92-93 million from $88-92 million. Quarterly cash burn improved 74% YoY to $2.4 million, aiding path to breakeven.
8 days agoSight Sciences Q3FY27 Results: Earnings call set for November 4
Sight Sciences will report Q3FY27 financial results on November 4, 2026. Conference call scheduled for 4:30 pm Eastern Time after market close. Webcast available for replay for at least 90 days post-event.
22 days agoHC Wainwright initiates Sight Sciences with Buy, $14 price target
HC Wainwright & Co. initiates coverage on Sight Sciences with a Buy rating. Analyst Yi Chen sets a price target of $14. The action represents the start of formal research tracking by the firm.
28 days agoSight Sciences secures FDA label expansion for TearCare dry eye treatment
Sight Sciences Inc. announced an FDA label expansion for its TearCare System, effective August 18, 2026. The update designates TearCare as the first and only MGD treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease. The revised indication also includes optional debridement capabilities, reinforcing the company’s focus on addressing the underlying physiological causes of dry eye disease through interventional technologies.
2mo agoSight Sciences Latest Results: Sales guidance raised to $88-92M
Sight Sciences has upgraded its FY2026 sales guidance to $88.000 million-$92.000 million, up from $83.000 million-$89.000 million. The new outlook beats the $86.083 million market estimate, indicating strong commercial execution.
3mo agoAetna covers Sight Sciences OMNI and SION for 25 million lives
Sight Sciences Inc. secured updated coverage from Aetna Inc. for its OMNI Surgical System and SION Surgical Instrument. The policy recognizes these devices as medically necessary for mild-to-moderate open-angle glaucoma, covering approximately 25 million commercial lives retroactively from July 14, 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Sight Sciences is now worth
$ 46.76
Resulting in a loss of
$ 53.24 (53.24%)
Note: Past profits do not guarantee future returns.
